About Cytocare Technologies
Cytocare Technologies is a Healthcare company based in Hyderabad (India). It provides comprehensive mammalian cell line development and manufacturing services. It operates on a B2B model. Its website cytocaretech.com draws about 681 thousand monthly visits. Its Indian entity Cytocare Technologies Private Limited reported revenue of ₹42.90 Cr. Its focus areas include Biotechnology, Cell Line Development and Manufacturing Services. Its competitors include Bionova Scientific, Avid Bioservices, Just Biotherapeutics, JHL Biotech and ProBioGen AG and 5 more; 4 of its 10 listed competitors have raised funding.
Company details
Cytocare Technologies provides comprehensive mammalian cell line development and manufacturing services, focusing on providing healthcare solutions, advancing biotech innovations, cell line development, and manufacturing services. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
- Headquarters Hyderabad, India
- SectorsHealthcare
- Website cytocaretech.com
- Legal Name Cytocare Technologies Private Limited
- Date of Incorporation 22 Oct, 2012
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹42.90 Cr
FY 2025 · +60% YoY
- Net Profit₹3.35 Cr
FY 2025 · 8% margin
- EBITDA₹4.84 Cr
FY 2025 · 11% margin
Associated legal entities of Cytocare Technologies
Cytocare Technologies operates through Cytocare Technologies Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cytocare Technologies Private Limited CIN U72200TG2012PTC083748 | Active | 22 Oct 2012 | Hyderabad, Telangana | ₹42.9 Cr | – | 2 | View details |
Board of directors of Cytocare Technologies Private Limited (Cytocare Technologies)
Cytocare Technologies Private Limited is the primary company behind Cytocare Technologies. The board of Cytocare Technologies Private Limited currently have 2 directors; the longest-serving is Nedun Chezhian Murugaiyan, appointed in 2020. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nedun Chezhian Murugaiyan DIN 08599255 | Director | 13 Jan 2020 | 6 yrs 9 mo | Cytocare Technologies Private Limited |
| Nedunchezhian Vijayalakshmi DIN 06381391 | Director | 08 Feb 2022 | 4 yrs 8 mo | Cytocare Technologies Private Limited |
Financials of Cytocare Technologies
Figures of Cytocare Technologies Private Limited, the primary company behind Cytocare Technologies, for FY 2025. Revenue was ₹42.90 Cr (+60% year on year). Net profit was ₹3.35 Cr (8% margin). EBITDA was ₹4.84 Cr (11% margin). Revenue has grown at a compounded annual rate of +35% over three years and +48% over five years.
- ₹42.90 CrRevenue · FY 2025 · +60% YoY
- ₹3.35 CrNet profit · 8% margin
- ₹4.84 CrEBITDA · 11% margin
- ₹1 LakhPaid-up capital
- +35%Revenue CAGR, 3 years
- +48%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Cytocare Technologies Private Limited are on its company page.
Detailed financial statements for Cytocare Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Cytocare Technologies
Cytocare Technologies has 10 listed competitors in our database, 4 of them funded. They include Bionova Scientific, Avid Bioservices, Just Biotherapeutics, JHL Biotech and ProBioGen AG, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bionovascientific.com | 2013 | Fremont, United States | $22M | 72 | Mammalian cell culture biologics are developed through contract research services. | |
| avidbio.com | 2002 | Orange, United States | – | 501 | Drug substance development, analytical, and compliance services are provided. | |
| justbiotherapeutics.com | 2014 | Seattle, United States | $123.51M | 79 | Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs | |
| jhlbiotech.com | 2012 | Hsinchu, Taiwan | $186.6M | – | Contract manufacturing solutions for biologics are provided to Asian companies. | |
| probiogen.de | 1994 | Berlin, Germany | – | – | Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars | |
| gallusbiopharma.com | 2010 | St. Louis, United States | – | – | Biologics CDMO specializing in mammalian cell line based manufacturing | |
| rentschler-biopharma.com | 1927 | Laupheim, Germany | – | 861 | Full-service CDMO for biopharmaceuticals | |
| mabplexinc.com | 2013 | Yantai, China | $130M | – | Biologics development and GMP manufacturing services are offered. | |
| polpharmabiologics.com | 2011 | Gdansk, Poland | – | – | Develops and manufactures biosimilar drugs and CDMO services for biotechnology applications. | |
| agcbio.com | 2018 | Bothell, United States | – | 1,290 | Provides contract development and manufacturing for biopharmaceuticals worldwide. |
Detailed competitors of Cytocare Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cytocare Technologies
The website of Cytocare Technologies (cytocaretech.com) receives about 680.7K visits a month.
- Monthly visits680.7K
▼ 6.7% vs previous month
Websites whose visitors overlap most with Cytocare Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Cytocare Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Cytocare Technologies (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cytocare Technologies
Cytocare Technologies is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Cytocare Technologies, Cytocare Technologies Private Limited, reported revenue of ₹42.90 Cr for FY 2025, up 60% year on year.
Cytocare Technologies provides comprehensive mammalian cell line development and manufacturing services, focusing on providing healthcare solutions, advancing biotech innovations, cell line development, and manufacturing services. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
Cytocare Technologies's top competitors include Avid Bioservices, Bionova Scientific and Rentschler Biopharma.
Cytocare Technologies operates through Cytocare Technologies Private Limited.
The legal entities of Cytocare Technologies currently have 2 directors, including Nedun Chezhian Murugaiyan, Nedunchezhian Vijayalakshmi.
The website of Cytocare Technologies receives about 681 thousand visits a month.